Drugs / ONTERODRIMER
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03933410 | Sep 2019 → Feb 2021 | urea cycle disorder | Kaleido Biosciences | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONTERODRIMER | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095354 ↗ |
| Known as | KB195 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03933410 ↗ |
| Modality | Other / unclassified | “KB195 is a novel glycan” NCT03933410 ↗ |